Siliq
(Brodalumab)Phase 3Monoclonal antibody
Brodalumab is used to treat moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches. It works by reducing inflammation in the body that causes these skin problems.[1] Siliq is currently being investigated across 13 indications[3], with its most advanced program in Phase 3.[1]
Siliq is one of 295 biologic programs targeting Palmoplantar Pustulosis. It is currently in Phase 3.
13
Indications
32
Total Trials
4
Active Trials
294
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Siliq
BBausch Health Americas, Inc.
Phase 3
Veramyst
GSKPreclinical
Xolair
RochePreclinical
Cinqair
TevaPreclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Spiriva
Boehringer IngelheimPreclinical
Arcoxia
NovartisPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Psoriasis14 trials
Show 11 more trials
Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis
Unknown status·—·Phase 4·NCT03478280·50 enrolled
Hidradenitis Suppurativa4 trials
Show 1 more trial
Psoriatic Arthritis2 trials
Arthritis2 trials
8 more indications
Pediatric1 trial
Moderate to Severe Crohn's Disease1 trial
MPA1 trial
Interaction1 trial
Immune-related Adverse Events1 trial
Brodalumab in the Treatment of Immune-Related Adverse Events
Recruiting·—·Phase 1·NCT06673329·11 enrolled
Asthma1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Feb 15, 2017
SILIQ
BLA BLA761032
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Brodalumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Interleukin-17 Receptor a Antagonist[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- BBausch Health Americas, Inc.